TABLE 1.
Pharmacokinetics of DRV and of ritonavir after administration of DRV/r alone (treatment A) and in combination with RFB (treatment C)
| Drug, parameter | Pharmacokinetics [mean ± SD or Tmaxa median (range)] with treatment: |
LS means ratio (90% CI) | |
|---|---|---|---|
| A (DRV/r) | C (DRV/r + RFB) | ||
| DRV | |||
| No. of volunteers | 16b | 11 | |
| Tmax (h) | 4.0 (1.0-9.0) | 3.0 (1.5-5.0) | |
| C0h (ng/ml) | 2,768 ± 1,077 | 4,825 ± 2,140 | 1.648 (0.975-2.783) |
| Cmin (ng/ml) | 2,349 ± 1,006 | 4,322 ± 1,955 | 1.745 (1.283-2.374) |
| Cmax (ng/ml) | 5,874 ± 1,637 | 8,719 ± 2,942 | 1.421 (1.213-1.665) |
| AUC12h (ng·h/ml) | 46,720 ± 15,430 | 74,590 ± 25,630 | 1.571 (1.281-1.926) |
| Ritonavir | |||
| No. of volunteers | 16b | 11 | |
| Tmax (h) | 4.5 (1.5-5.0) | 4.0 (1.0-6.0) | |
| C0h (ng/ml) | 293.6 ± 154.7 | 330.1 ± 252.1 | 1.114 (0.544-2.281) |
| Cmin (ng/ml) | 176.4 ± 87.56 | 233.2 ± 131.1 | 1.307 (0.877-1.946) |
| Cmax (ng/ml) | 918.0 ± 404.1 | 1,379 ± 640.5 | 1.682 (1.236-2.289) |
| AUC12h (ng·h/ml) | 5,394 ± 2,281 | 8,335 ± 3,772 | 1.657 (1.271-2.159) |
a
Tmax, time to maximum plasma concentration.
b
n = 15 volunteers for C0h.